4.4 Article

Malformations, Genetic Abnormalities, and Wilms Tumor

期刊

PEDIATRIC BLOOD & CANCER
卷 61, 期 1, 页码 140-144

出版社

WILEY
DOI: 10.1002/pbc.24709

关键词

genetic abnormality; hemihypertrophy; nephroblastoma; predisposition syndrome; Wilms tumor; WT1

资金

  1. Annenberg Foundation

向作者/读者索取更多资源

BackgroundWilms Tumor (WT) can occur in association with tumor predisposition syndromes and/or with clinical malformations. These associations have not been fully characterized at a clinical and molecular genetic level. This study aims to describe clinical malformations, genetic abnormalities, and tumor predisposition syndromes in patients with WT and to propose guidelines regarding indications for clinical and molecular genetic explorations. ProcedureThis retrospective study analyzed clinical abnormalities and predisposition syndromes among 295 patients treated for WT between 1986 and 2009 in a single pediatric oncological center. ResultsClinically identified malformations and predisposition syndromes were observed in 52/295 patients (17.6%). Genetically proven tumor predisposition syndromes (n=14) frequently observed were syndromes associated with alterations of the chromosome WT1 region such as WAGR (n=6) and Denys-Drash syndromes (n=3), syndromes associated with alterations of the WT2 region (Beckwith-Wiedeman syndrome, n=3), and Fanconi anemia (n=2). Hemihypertrophy and genito-urinary malformations (n=12 and n=16, respectively) were the most frequently identified malformations. Other different syndromes or malformations (n=10) were less frequent. Median age of WT diagnosis was significantly earlier for children with malformations than those without (27 months vs. 37 months, P=0.0009). There was no significant difference in terms of 5-year EFS and OS between WT patients without or with malformations. ConclusionsThe frequency of malformations observed in patients with WT underline the need of genetic counseling and molecular genetic explorations for a better follow-up of these patients, with a frequently good outcome. A decisional tree, based on clinical observations of patients with WT, is proposed to guide clinicians for further molecular genetic explorations. Pediatr Blood Cancer 2014;61:140-144. (c) 2013 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据